After GLP-1: Can Amylin Analogs Build The Next Frontier in Diabetes Treatment?  2025-07-24 
  Explore the future beyond GLP-1 drugs in diabetes and obesity treatment with amylin analogs. This article dives into the clinical promise, market opportunities, key challenges, and licensing strategies for amylin-based therapies, highlighting why they may redefine the next wave of metabolic medicine. Learn how Unibest supports pharma companies in licensing and accelerating amylin drug development. 
Read More